Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- Trial result Spotlight
Bladder and urothelial cancer
Enfortumab vedotin (Nectin-4 ADC) + pembrolizumab (PD-1) sustains 33.6-mo OS and high CR conversion vs platinum chemo in 1L la/mUC
Enfortumab vedotin is a Nectin-4–directed antibody–drug conjugate (MMAE payload) combined with pembrolizumab, a PD-1 inhibitor; in the randomized Phase 3 EV-302/KEYNOTE-A39 trial (NCT04223856), previously untreated…
NCT04223856 - Trial result Spotlight
Neuroendocrine and adrenal tumors
[177Lu]Lu-edotreotide (SSTR2-targeted PRRT) beats everolimus on PFS in progressive GEP-NETs (COMPETE)
[177Lu]Lu-edotreotide is a somatostatin receptor (SSTR; high affinity for SSTR2)–targeted peptide receptor radionuclide therapy (PRRT; [177LuDOTA]-TOC) compared head-to-head with everolimus (oral mTOR inhibitor) in…
NCT03049189 - Trial result Spotlight
Colorectal cancer
Toripalimab (PD-1) + celecoxib (COX-2) lifts pCR to 89% in dMMR/MSI-H locally advanced CRC (PICC-2)
Toripalimab is an anti–PD-1 monoclonal antibody, and celecoxib is an oral COX-2 inhibitor hypothesized to reshape the inflammatory tumor microenvironment to potentiate checkpoint blockade. In the open-label,…
NCT03926338 - Trial result Spotlight
Breast cancer
Inavolisib (PI3Kα inhibitor/p110α degrader) more than doubles PFS vs placebo in Asian PIK3CA-mut HR+/HER2– aBC
In the Phase 3 INAVO120 trial (NCT04191499), inavolisib (INAVO) is an oral, selective PI3Kα inhibitor that also promotes degradation of mutant p110α, combined with palbociclib (CDK4/6 inhibitor) plus fulvestrant…
NCT04191499 - Trial result Spotlight
Breast cancer
Durvalumab (PD-L1) + trastuzumab deruxtecan (HER2 ADC) delivers 62% ORR but 21% ILD in 1L HR−/HER2-low mBC
Durvalumab is an anti–PD-L1 checkpoint inhibitor and trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload; the combo was tested as first-line…
NCT03742102 - Trial result Spotlight
Lymphoma
Epcoritamab (CD3×CD20) + R2 delivers higher CR/OS vs real‑world R2/CIT in R/R follicular lymphoma
Epcoritamab is a subcutaneous CD3×CD20 bispecific antibody; here it was combined with lenalidomide (immunomodulatory agent) plus rituximab (anti‑CD20) as a chemotherapy-free regimen. In an adjusted comparative…
NCT04663347 - Trial result Spotlight
Multiple myeloma
Linvoseltamab (BCMA×CD3) tops elranatamab on ORR/≥CR in unanchored MAIC of TCE RRMM
Linvoseltamab is an off-the-shelf BCMA×CD3 T-cell–engaging bispecific antibody compared here with elranatamab, another BCMA×CD3 bispecific, using an unanchored matching-adjusted indirect comparison across LINKER-MM1…
NCT03761108 - Trial result Spotlight
Multiple myeloma
Talquetamab (GPRC5D×CD3) + daratumumab ± pomalidomide sharply improves 24-mo PFS in RRMM
Talquetamab is a GPRC5D×CD3 T-cell–redirecting bispecific antibody, combined here with daratumumab, an anti-CD38 monoclonal antibody, with or without pomalidomide, an immunomodulatory agent. In the Phase 3…
NCT05455320 - New trial Spotlight
Prostate cancer
Phase 3 rinzimetostat (ORIC-944) EED/PRC2 inhibitor + darolutamide AR antagonist in post-abiraterone mCRPC
ORIC Pharmaceuticals’ Himalayas-1 (NCT07723248) is a randomized, open-label Phase 3 study in metastatic castration-resistant prostate cancer (mCRPC) that has progressed after abiraterone acetate, testing whether…
NCT07723248 Registrational - New trial Spotlight
Pancreatic cancer
Phase 2 ASP-1929 EGFR-targeted photoimmunotherapy (cetuximab–IR700 conjugate) in pancreatic cancer.
This open-label Phase 2 BrUOG 438 study tests ASP-1929 photoimmunotherapy (PIT) as a peri-operative, EGFR-targeted cytotoxic immune-activating approach for locally advanced or borderline resectable pancreatic…
NCT07698613 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase 1 177Lu-DTPA-omburtamab compartmental radioimmunotherapy targets B7-H3 (CD276)
This Phase 1, dose-escalation compartmental radioimmunotherapy (cRIT) study tests intrathecal/intraventricular delivery of 177Lu-DTPA-omburtamab, a B7-H3 (CD276)-targeting murine monoclonal antibody chelated with…
NCT07698899 First-in-human - Trial result Spotlight
Non-small cell lung cancer
Selpercatinib (RET inhibitor) slashes recurrence risk in resected RET fusion+ NSCLC (2-year EFS 92% vs 61%)
Selpercatinib is an oral, highly selective RET tyrosine kinase inhibitor (CNS-penetrant) tested as adjuvant targeted therapy in the Phase 3, double-blind LIBRETTO-432 trial (NCT04819100) in RET fusion–positive stage…
NCT04819100 - Trial result Spotlight
Non-small cell lung cancer
Sunvozertinib (EGFR exon20ins TKI) extends PFS vs carbo/pem chemo in 1L EGFR exon20ins NSCLC (WU-KONG28)
Sunvozertinib is an oral EGFR tyrosine kinase inhibitor designed to inhibit EGFR exon 20 insertion mutations, tested head-to-head vs platinum doublet in the confirmatory multinational Phase 3 WU-KONG28 trial…
NCT05668988 - Trial result Spotlight
Skin cancer (non-melanoma)
Pembrolizumab (PD-1) cuts MCC-specific relapse events in resected Merkel cell carcinoma, with signal for better distant control
Pembrolizumab is an anti–PD-1 checkpoint inhibitor tested as adjuvant therapy in the randomized Phase III STAMP trial (EA6174; NCT03712605) after complete resection of stage I (no SLNB) to IIIB Merkel cell carcinoma:…
NCT03712605 - Trial result Spotlight
Melanoma
Intismeran autogene + pembrolizumab sustains 5-year RFS/DMFS benefit in resected melanoma
Intismeran autogene, also known as V940 or mRNA-4157, is Moderna/Merck’s individualized neoantigen mRNA therapy encoding up to 34 patient-specific tumor neoantigens, designed to broaden tumor-specific T-cell…
NCT03897881 - Trial result Spotlight
Acute myeloid leukemia and MDS
Ziftomenib (menin inhibitor) + venetoclax/azacitidine drives 46% CRc and frequent MRD negativity in R/R NPM1-mut AML
Ziftomenib is a potent, selective, oral menin inhibitor evaluated with venetoclax (BCL-2 inhibitor) plus azacitidine (hypomethylating agent) in KOMET-007, a Phase 1a/1b dose-escalation/expansion study in adults with…
NCT05735184 - Trial result Spotlight
Colorectal cancer
EC (encorafenib+BRAF inhibitor) + cetuximab (EGFR mAb) + FOLFIRI cuts PFS risk ~56% in 1L BRAF V600E mCRC
Encorafenib (BRAF inhibitor) plus cetuximab (EGFR antibody) was combined with FOLFIRI chemotherapy as first-line treatment in BREAKWATER Cohort 3 (Phase 3, open-label; NCT04607421) for untreated BRAF V600E–mutant…
NCT04607421 - Trial result Spotlight
Brain and CNS tumors
Cesium-131 tile brachytherapy (TBRT) slashes surgical-bed recurrence vs post-op SRT in resected brain mets
ROADS (NCT04365374) was an open-label, randomized Phase 3 trial across 32 US centers comparing resection + post-operative stereotactic radiation therapy (SRT; standard approach for cavity control) vs resection +…
NCT04365374 - New trial Spotlight
Kidney cancer
Phase 3 MO-03 live biotherapeutic (butyrate‑producing Clostridium butyricum ) added to PD‑1/CTLA‑4±VEGFR TKI first-line ccRCC
This SWOG Cancer Research Network Phase 3 double-blind, placebo-controlled trial (BioFront; also listed as SWOG S2419) tests whether MO-03—a live biotherapeutic containing a butyrate‑producing bacterium *Clostridium…
NCT07383441 Registrational - New trial Spotlight
Non-small cell lung cancer
Phase 3 CAN-2409 HSV-tk adenoviral gene therapy + prodrug with PD-1 blockade in NSCLC
Candel Therapeutics’ Phase 3 AURORA trial randomizes patients 1:1 to either intratumoral aglatimagene besadenovec (CAN-2409)—a replication-deficient adenoviral vector delivering the HSV-tk “suicide gene”—plus oral…
NCT07660094 Registrational - New trial Spotlight
Multiple myeloma
Phase 3 linvoseltamab BCMA×CD3 bispecific antibody versus daratumumab anti-CD38 in high-risk SMM.
This Phase 3, randomized, open-label study (LINKER-SMM2) tests whether Regeneron’s linvoseltamab-gcpt—an off-the-shelf T-cell–engaging bispecific monoclonal antibody that binds BCMA on plasma cells and CD3 on T…
NCT07393282 Registrational - Trial result Spotlight
Kidney cancer
Pembrolizumab (PD-1) + high-dose IL-2 (T-cell–activating cytokine) drives 42% CRs and >84-mo OS in 1L ccRCC
Pembrolizumab (anti–PD-1) combined with high-dose interleukin-2 (aldesleukin; pleiotropic T-cell/NK-cell activating cytokine) was evaluated as a fixed-duration, single-arm Phase 2 regimen in treatment-naive advanced…
NCT02964078 - Trial result Spotlight
Kidney cancer
CaboNivo (cabozantinib VEGFR/MET/AXL TKI + nivolumab PD-1) drives 43% ORR in metastatic non–clear cell RCC—chromophobe remains refractory
Cabozantinib (a multikinase VEGFR/MET/AXL inhibitor) plus nivolumab (PD-1 antibody) was evaluated in an investigator-initiated Phase 2 study in advanced/metastatic non–clear cell RCC with 0–1 prior systemic therapies…
NCT03635892 - Trial result Spotlight
Kidney cancer
CBM588 (Clostridium butyricum live biotherapeutic) + ICB combos drives big PFS/ORR gains in dysbiotic 1L mRCC
CBM588 is an oral *Clostridium butyricum*–based live biotherapeutic intended to modulate the gut microbiome; here it was added to standard first-line immune checkpoint–based regimens (nivolumab/ipilimumab or…
NCT03829111 - Trial result Spotlight
Neuroendocrine and adrenal tumors
Sacituzumab govitecan (TROP2–SN-38 TOP1 ADC) + berzosertib (ATR inhibitor) lifts disease control to 86% in platinum-refractory EPSCC
Berzosertib is an IV ATR (replication-stress response) inhibitor combined here with either conventional TOP1 inhibition (topotecan) or tumor-targeted TOP1 payload delivery via the TROP2-directed ADC sacituzumab…
NCT03896503 - Trial result Spotlight
Head and neck cancer
Emiltatug Ledadotin B7-H4 ADC Reaches 40% ORR in Aggressive ACC
Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4–directed ADC with an auristatin F-HPA microtubule-inhibitor payload, evaluated in a Phase 1 dose-escalation/backfill cohort enriched for aggressive adenoid cystic…
NCT05377996 - Trial result Spotlight
Multiple myeloma
DaraKPd (anti-CD38 mAb + proteasome inhibitor + IMiD) delivers 38.3-mo mPFS in CD38-naïve RRMM
Daratumumab (anti-CD38 monoclonal antibody) combined with carfilzomib (proteasome inhibitor), pomalidomide (IMiD), and dexamethasone (DaraKPd) was evaluated in a phase 2 MMRC study in relapsed/refractory multiple…
NCT01665794 - Trial result Spotlight
Multiple myeloma
Durcabtagene autoleucel (PHE885), a rapid-manufactured BCMA CAR-T, posts 98% ORR and 55% sCR in r/r multiple myeloma
Durcabtagene autoleucel (also known as PHE885) is an autologous BCMA-directed CAR-T made on a rapid manufacturing platform intended to preserve stem-like T-cell features. In Part A of a Phase 1, dose-escalation study…
NCT04318327 - Trial result Spotlight
Acute myeloid leukemia and MDS
AZA/VEN + ivosidenib (IDH1 inhibitor) drives 95% ORR and 79% 3-year OS in unfit IDH1-mut AML
Azacitidine (DNA hypomethylating agent) + venetoclax (BCL-2 inhibitor) + ivosidenib (mutant IDH1 inhibitor) was evaluated as a frontline “triplet” in a multicenter Phase Ib/II study (NCT03471260) for newly diagnosed…
NCT03471260 - Trial result Spotlight
Acute myeloid leukemia and MDS
Mesutoclax (ICP-248), a selective BCL-2 inhibitor, drives 86% cCR with azacitidine in treatment-naïve AML
Mesutoclax (ICP-248) is a next-gen, highly selective BCL-2 inhibitor (positioned as a venetoclax-like backbone with a “cleaner” PK profile) tested with azacitidine in the ongoing global Phase 1 ICP-CL-01205…
NCT06656494
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.